Three-dimensional Ultrasound Applying in Assessment of Intrauterine Adhesions

Sponsor
Fu Xing Hospital, Capital Medical University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04930913
Collaborator
(none)
600
1
35.9
16.7

Study Details

Study Description

Brief Summary

In this prospective, multicenter, large-scale study,the investigators wish to examine the accuracy of several three-dimensional ultrasound anatomical and vascular parameters in diagnosing IUA when compared to the gold standard of hysteroscopy,and to assess the value of 3D US applying in prognosis of intrauterine adhesions.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Three-dimensional Ultrasound

Detailed Description

  1. Study Design This is a prospective, multicenter, large-scale diagnostic testing. We use hysteroscopy finding as standard reference.

  2. Study population 600 patients from three tertiary hospitals suspected of having IUA will be prospectively recruited. Thorough assessment including previous reproductive and surgical history as well as menstrual pattern will be performed.

  3. Study Procedure 3.1 Diagnosis

IUA will be diagnosed in coronal plane, based on a suggestion reported by a Taiwanese study.

The morphological characteristics of the endometrium suggesting IUA include as follow:
  • marginal irregularity (in coronal plane)

  • defects (interrupted endometrial line)

  • obliteration (undetectable endometrium suggesting extensive adhesion)

  • fibrosis or calcification (hyperechoic lesion without posterior shadowing, or with posterior shadowing) 3.2 Ultrasound

  • Transvaginal Ultrasound will be performed in luteal phase.

  • Using E10 Voluson GE with 3D/4D TV probe.

  • Scan and rendering will be performed in a standardized technique (omniview mode).

  • Several parameters will be measured including endometrial volume, uterine volume, vascularization (VI FI VFI).

3.3 Hysteroscopy

  • Hysteroscopic exam will be used as the gold standard for the diagnosis of intrauterine adhesions.

  • hysteroscopy will confirm the presence, extent, and morphological characteristics of adhesions and the quality of the endometrium.

3.4 Surgical technique

  • Hysteroscopic surgery will be performed in a standardized manner.

  • The severity and extent of intrauterine adhesions will be scored according to different classification systems. (ESGE/AFS/China consensus)

  • a Foley-catheter filled with 3.0ml normal saline will be inserted into the uterus for 5-7 days after surgery.

3.5 Postoperative treatments

  • All subjects will be treated with Hormone therapy for at least 8 weeks

  • A second-look hysteroscopy will be carried out 4 weeks after surgery, a third-look hysteroscopy will be carried out 12 weeks after surgery

  • A second-look 3D US will be carried out in luteal phase after two menstrual peroid postoperatively.

3.6 Follow up

  • Follow-up styles: the doctor's outpatient review, telephone, WeChat and so on.

  • Follow-up time:3 months, 6months, 12 months after the operation.

  • Follow up the results of hysteroscopy and 3D US at 3 months after the operation and the menstrual improvement at 6months after the operation and pregnancy outcomes at 12 months after the operation

Study Design

Study Type:
Observational
Anticipated Enrollment :
600 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
The Value of Three-dimensional Ultrasound Applying in Pre and Postoperative Assessment and Prognosis of Intrauterine Adhesions
Actual Study Start Date :
Jul 1, 2020
Anticipated Primary Completion Date :
Jun 30, 2022
Anticipated Study Completion Date :
Jun 30, 2023

Outcome Measures

Primary Outcome Measures

  1. Endometrial volume [1 year]

    Endometrial volume will be measured in in luteal phase by 3D US

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 40 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • women aged 20-40

  • oligomenorrhea or amenorrhea

  • BMI 18-30

  • regular menstruation

  • written consent obtained

Exclusion Criteria:
  • Hypothalamic amenorrhea, pituitary amenorrhea and ovarian amenorrhea

  • Patients with uterine fibroids, adenomyosis, uterine malformation and endometrial polyps

  • Patients with uterine artery embolization

  • History of endometrial hyperplasia

  • Irregular menstruation

  • Patients with severe complications

  • Patients with hypoovarian function

Contacts and Locations

Locations

Site City State Country Postal Code
1 Fu Xing Hospital, Capital Medical University Beijing China 100038

Sponsors and Collaborators

  • Fu Xing Hospital, Capital Medical University

Investigators

  • Study Chair: Li Tinchiu, Fuxing Hospital,Capital Medical University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Xiaowu Huang, Director of department, Fu Xing Hospital, Capital Medical University
ClinicalTrials.gov Identifier:
NCT04930913
Other Study ID Numbers:
  • 2020-1-7027
First Posted:
Jun 18, 2021
Last Update Posted:
Jun 18, 2021
Last Verified:
Jun 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 18, 2021